Most cited papers from Novavax (United States)

Novavax (United States)

What are the most cited papers from Novavax (United States)?

The most cited paper from Novavax (United States) is "Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant" (Vivek Shinde et al., 2021), with 667 citations. Next come "SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice" (529) and "Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial" (473).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 59 papers. Every paper with more than 74 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant Vivek Shinde et al. · New England Journal of Medicine Open access	5 May 2021	667
2	SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice Jing-Hui Tian et al. · Nature Communications Open access	14 Jan 2021	529
3	Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial Mehreen S. Datoo et al. · The Lancet Open access	May 2021	473
4	Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico Lisa M. Dunkle et al. · New England Journal of Medicine Open access	15 Dec 2021	461
5	Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants Shabir Ahmed Madhi et al. · New England Journal of Medicine Open access	29 Jul 2020	439
6	Severe Morbidity and Mortality Associated With Respiratory Syncytial Virus Versus Influenza Infection in Hospitalized Older Adults Bradley K. Ackerson, Hung Fu Tseng, Lina S. Sy et al. · Clinical Infectious Diseases Open access	16 Nov 2018	412
7	SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines Xiaoying Shen, Haili Tang, Charlene B. McDanal et al. · Cell Host & Microbe Open access	7 Mar 2021	394
8	Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate Sandhya Bangaru, Gabriel Ozorowski, Hannah L. Turner et al. · Science Open access	20 Oct 2020	385
9	Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice Christopher Michael Coleman, Ye V. Liu, Haiyan Mu et al. · Vaccine Open access	13 Apr 2014	306
10	Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial Mehreen S. Datoo et al. · The Lancet Infectious Diseases Open access	7 Sep 2022	300
11	Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin Rick A. Bright, Donald M. Carter, Shannon Daniluk et al. · Vaccine	16 Feb 2007	289
12	Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice Peter Pushko, Terrence M. Tumpey, F. R. Bu et al. · Vaccine	16 Aug 2005	249
13	NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge Mimi Guebre‐Xabier, Nita Patel, Jing-Hui Tian et al. · Vaccine Open access	23 Oct 2020	241
14	Cross-Clade Protective Immune Responses to Influenza Viruses with H5N1 HA and NA Elicited by an Influenza Virus-Like Particle Rick A. Bright, Donald M. Carter, Corey J. Crevar et al. · PLoS ONE Open access	29 Jan 2008	240
15	Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351 Xiaoying Shen, Haili Tang, Rolando Pajón et al. · New England Journal of Medicine Open access	7 Apr 2021	226
16	A Novel Surfactant Nanoemulsion with Broad‐Spectrum Sporicidal Activity againstBacillusSpecies Tarek Hamouda, Michael M. Hayes, Zhengyi Cao et al. · The Journal of Infectious Diseases	Dec 1999	205
17	Multi-functional nanocarriers for targeted delivery of drugs and genes Lara Scheherazade Jabr-Milane, Lilian van Vlerken, Harikrishna Devalapally et al. · Journal of Controlled Release	30 Apr 2008	170
18	Burden of respiratory syncytial virus infection in community-dwelling older adults in Europe (RESCEU): an international prospective cohort study Koos Korsten, Niels Adriaenssens, Samuel Coenen et al. · European Respiratory Journal Open access	15 Oct 2020	168
19	A Recombinant Viruslike Particle Influenza A (H7N9) Vaccine Louis F Fries, Gale Smith, Gregory M. Glenn · New England Journal of Medicine Open access	13 Nov 2013	167
20	Clinical Features, Severity, and Incidence of RSV Illness During 12 Consecutive Seasons in a Community Cohort of Adults ≥60 Years Old Edward A. Belongia, Jennifer P. King, Burney A. Kieke et al. · Open Forum Infectious Diseases Open access	27 Nov 2018	165
21	Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model Harikrishna Devalapally, Dinesh B. Shenoy, Steven R. Little et al. · Cancer Chemotherapy and Pharmacology	21 Jul 2006	156
22	A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age Gregory M. Glenn, Louis F Fries, David Nigel Thomas et al. · The Journal of Infectious Diseases Open access	10 Aug 2015	155
23	Estimates of hospitalization attributable to influenza and RSV in the US during 1997–2009, by age and risk status Gonçalo Matias, Robert J. Taylor, François Haguinet et al. · BMC Public Health Open access	21 Mar 2017	154
24	Respiratory Syncytial Virus Fusion Glycoprotein Expressed in Insect Cells Form Protein Nanoparticles That Induce Protective Immunity in Cotton Rats Gale Smith, Rama Raghunandan, Yingyun Wu et al. · PLoS ONE Open access	30 Nov 2012	151
25	Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial Seth Toback et al. · The Lancet Respiratory Medicine Open access312 authors	17 Nov 2021	149
26	Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination Matthew J. Gorman et al. · Cell Reports Medicine Open access	31 Aug 2021	147
27	Intranasal Vaccination with 1918 Influenza Virus-Like Particles Protects Mice and Ferrets from Lethal 1918 and H5N1 Influenza Virus Challenge Lucy A. Perrone, Attiya Ahmad, Vic Veguilla et al. · Journal of Virology Open access	26 Mar 2009	146
28	Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine Gregory M. Glenn, Gale Smith, Louis F Fries et al. · Vaccine	12 Nov 2012	144
29	Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico Constantino López-Macı́as, Eduardo Antonio Ferat-Osorio, Alejandra V. Tenorio-Calvo et al. · Vaccine Open access	3 Aug 2011	137
30	Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice Karin Lövgren Bengtsson, Haifeng Song, Linda Stertman et al. · Vaccine Open access	25 Feb 2016	133
31	H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses Kutubuddin Mahmood, Rick A. Bright, Nutan Mytle et al. · Vaccine	15 Aug 2008	132
32	Newcastle Disease Virus-Like Particles Containing Respiratory Syncytial Virus G Protein Induced Protection in BALB/c Mice, with No Evidence of Immunopathology Matthew R. Murawski, Lori W. McGinnes, Robert W. Finberg et al. · Journal of Virology Open access	5 Nov 2009	130
33	Severe Morbidity and Short- and Mid- to Long-term Mortality in Older Adults Hospitalized with Respiratory Syncytial Virus Infection Hung Fu Tseng, Lina S. Sy, Bradley K. Ackerson et al. · The Journal of Infectious Diseases	19 Jun 2020	129
34	Global and Regional Burden of Hospital Admissions for Pneumonia in Older Adults: A Systematic Review and Meta-Analysis Ting Shi et al. · The Journal of Infectious Diseases ReviewOpen access	19 Feb 2019	128
35	The epidemiology of medically attended respiratory syncytial virus in older adults in the United States: A systematic review Ann D. Colosia, Jin Yang, Eric Hillson et al. · PLoS ONE ReviewOpen access	10 Aug 2017	126
36	Efficacy of Two Alternate Vaccines Based onPlasmodium falciparumMerozoite Surface Protein 1 in anAotusChallenge Trial Anthony W. Stowers, Vittoria Cioce, Richard L. Shimp et al. · Infection and Immunity Open access	Mar 2001	126
37	Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo Thomas C Luke et al. · Science Translational Medicine Open access	17 Feb 2016	119
38	The Matrix-M™ adjuvant: A critical component of vaccines for the 21 st century Linda Stertman, Anna-Karin E. Palm, Behdad Zarnegar et al. · Human Vaccines & Immunotherapeutics Open access	2 Jan 2023	116
39	Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials Devan V. Mehrotra et al. · Annals of Internal Medicine Open access	22 Oct 2020	116
40	Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial Neil T. Formica, Raburn M. Mallory, Gary R. Albert et al. · PLoS Medicine Open access	Oct 2021	113
41	Development of influenza H7N9 virus like particle (VLP) vaccine: Homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus Gale Smith, David C. Flyer, Rama Raghunandan et al. · Vaccine Open access	26 Jul 2013	109
42	Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial Youyi Fong et al. · Nature Communications Open access	19 Jan 2023	106
43	Assembly and Immunological Properties of Newcastle Disease Virus-Like Particles Containing the Respiratory Syncytial Virus F and G Proteins Lori W. McGinnes, Kathryn A. Gravel, Robert W. Finberg et al. · Journal of Virology Open access	28 Oct 2010	104
44	Safety and Immunogenicity of a Respiratory Syncytial Virus Fusion (F) Protein Nanoparticle Vaccine in Healthy Third-Trimester Pregnant Women and Their Infants Flor M. Muñoz, Geeta Krishna Swamy, Somia Perdow Hickman et al. · The Journal of Infectious Diseases	Aug 2019	100
45	Efficacy and safety of a patch vaccine containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala R.H. Behrens, Jakob P. Cramer, Tomáš Jelı́nek et al. · The Lancet Infectious Diseases	28 Nov 2013	100
46	A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age Allison August, Gregory M. Glenn, Eloi P. Kpamegan et al. · Vaccine Open access	Jun 2017	99
47	Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza Peter Pushko, Terrence M. Tumpey, Neal Van Hoeven et al. · Vaccine	10 Mar 2007	98
48	H5N1 Virus-Like Particle Vaccine Elicits Cross-Reactive Neutralizing Antibodies That Preferentially Bind to the Oligomeric Form of Influenza Virus Hemagglutinin in Humans Surender Khurana, Jian Wu, Nitin Verma et al. · Journal of Virology Open access	25 Aug 2011	98
49	MERS-CoV spike nanoparticles protect mice from MERS-CoV infection Christopher Michael Coleman, Thiagarajan Venkataraman, Ye V. Liu et al. · Vaccine Open access	23 Feb 2017	96
50	Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries) Timo Vesikari, Robbin F. Itzler, David O. Matson et al. · International Journal of Infectious Diseases Open access	Dec 2007	93

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.